KALV
KalVista Pharmaceuticals, Inc. (KALV) Management Analysis (2026)
Overall Score
Capital Allocation
Management maintains a strong liquidity position with a current ratio of 5.58x and cash ratio of 4.00x.
The balance sheet remains lightly levered on a net debt basis, with net debt to EBITDA at -0.47x.
Capital deployment appears conservative, with minimal capex intensity and no dividend payout.
Operational Execution
Gross margin remains very high at 92.0%, indicating strong product-level economics.
However, profitability is still deeply negative, with EBITDA margin at -101.1% and net margin at -119.4%.
Cash generation remains weak, with operating cash flow and free cash flow both negative on a TTM basis.
Governance And Incentives
No fresh news or disclosures indicate a material change in governance or incentive alignment this month.
Management assessment remains anchored to the existing operating and capital structure profile.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on KalVista Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

